| Date | Title | Description | |
|---|---|---|---|
| 23 Nov 2022 | On business and financial situation | The Company releases the presentation related to its strategy update because of its 2022 Capital Markets Day | Download |
| 04 Nov 2022 | On business and financial situation | The Company releases the press release related to the first nine months of 2022 financial results | Download |
| 04 Nov 2022 | On business and financial situation | The Company releases the first nine months 2022 financial results presentation | Download |
| 15 Mar 2022 | On significant placements in financial instruments | Bestinver announces details of an accelerated book building process of approximately 5% of the share capital of Laboratorios Farmacéuticos Rovi, S.A. | Download |
| 14 Mar 2022 | On significant placements in financial instruments | Bestinver announces the beginning of an accelerated book building process approximately 5% of the share capital of Laboratorios Farmacéuticos Rovi, S.A. | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 05 Nov 2021 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted on 3 and 4 November | Download |
| 03 Nov 2021 | On business and financial situation | The Company releases the first nine months 2021 financial results presentation | Download |
| 03 Nov 2021 | On business and financial situation | The Company releases the press release related to the first nine months 2021 financial results | Download |
| 21 Oct 2021 | Liquidity and counterparty agreements | Download | |
| 21 Oct 2021 | On business and financial situation | The Company informs of the delay in the decision on Risperidone ISM® by the U.S. Food and Drug Administration (“FDA”). | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 06 Apr 2017 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the first quarter of 2017 | Download |
| 13 Mar 2017 | Otros sobre negocio y situación financiera | The Company releases the presentation related to its biosimilar of Enoxaparin | Download |
| 07 Mar 2017 | Otros sobre negocio y situación financiera | ROVI informs that the Decentralised procedure used for the registration of its biosimilar of enoxaparin has been completed with positive outcome | Download |
| 16 Feb 2017 | Otros sobre Gobierno Corporativo | The Company informs about the agreements adopted by the Board of Directors | Download |
| 16 Feb 2017 | Informe anual de remuneraciones de los consejeros | ROVI releases the 2016 annual report regarding remuneration of the members of the Board of Directors | Download |